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Objectives: The purpose of this study is to examine clinical 
and pathological features and chemotherapy in the elderly with 
metastatic non-small cell lung cancer (NSCLC), especially in 
patients aged 75 years and older. 
Methods: From the databases at two teaching hospitals during 
the period from January 1999 to December 2013, medical records 
of lung cancer patients were retrospectively reviewed. The 
patient population was divided into two age groups: 75 years 
or older (the ≥75 age group) and less than 75 years (the <75 
age group). Time trends were also studied in three time periods: 
1999-2003, 2004-2008, and 2009-2013. The years 2004 and 2009 
were chosen as cutoff points because of the introduction of 
gefitinib and bevacizumab respectively around these years to 
treat NSCLC patients. 
Results: Patients aged 75 years and older comprised 27.3% of 
772 consecutive stage IV NSCLC patients; there was an increase 
in the proportion of ≥75 age patients treated with chemotherapy; 
a trend of improvement in survival of these patients was found. 
No statistical difference was found in survival between the two 
age groups of patients treated with chemotherapy (p=0.883). Age 
≥75 was not an unfavorable prognostic factor in multivariate 
analysis. 
Conclusion: In order to improve survival, detection of 
appropriate candidates for effective chemotherapy is indeed 
essential even for the ≥75 age group of stage IV NSCLC patients. 
 
 





Lung cancer in the elderly is an increasingly common problem 
faced by chest physicians and thoracic surgeons [1-5]. Elderly 
patients tend to tolerate toxic medical treatments poorly 
compared to their younger counterparts, because of the comorbid 
diseases related to age. Clinical trials of platinum-based 
chemotherapy for selected “fit” elderly patients in good 
condition have been conducted, attracting attention to the 
utility of such therapy for the elderly [6-14]. Especially in 
non-small cell lung cancer (NSCLC), the development of new drugs 
such as epidermal growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKIs) and vascular endothelial growth factor 
(VEGF) inhibitors, higher standards of medical care, and wider 
availability of health services may change survival rates of 
elderly stage IV NSCLC patients. 
To address the question of whether the overall survival 
of lung cancer patients 75 years of age or older has improved, 
we performed a retrospective study using clinical data from 
consecutive patients with NSCLC diagnosed at our two tertiary 
hospitals. We also focused on the role of performance status 
(PS), comorbid disease, and treatment modalities including 
chemotherapy on survival of the elderly patients aged 75 years 
or older. 
 
 Patients and methods 
Clinicopathological data for all the consecutive patients 
with NSCLC were obtained by retrospective review from the 
databases at University of Tsukuba Hospital and Tsukuba Medical 
Center Hospital and Regional Cancer Center. All the patients 
were diagnosed pathologically and treated between 1999 and 
December 2013 at these two tertiary hospitals. Pathological 
diagnosis was defined by the WHO classification [15]. Staging 
was recorded for patients with NSCLC according to TNM 
classification [16]. Demographic data, including age, gender, 
and PS, were retrieved from their medical records along with 
the specific details of their cancer. This study conformed to 
the Ethical Guidelines for Clinical Studies by the Ministry of 
Health, Labor and Welfare of Japan. The entire patient 
population was divided into two age groups: 75 years or older 
(the ≥75 age group) at diagnosis, and less than 75 years (the 
<75 age group) [17-19]. The median survival time (MST) was 
compared between the two age groups as defined by gender, 
histologic subtype, stage, and therapy. Three predefined time 
periods, that is patients presenting between 1999 and 2003, 
between 2004 and 2008, and between 2009 and 2013 were used for 
comparison of survival. The years 2004 and 2009 were chosen as 
cutoff points because of the introduction of gefitinib and 
bevacizumab respectively around these years to treat NSCLC 
patients.  
Differences in distribution of subpopulations between the 
two age groups and three time periods were analyzed using a 
Chi-square test. The Kaplan–Meier method was used to assess 
survival curves and the log-rank test to evaluate the 
statistical significance of differences between the two groups 
[20, 21]. Length of survival was defined as the interval in 
months from date of initial therapy or supportive care until 
date of death or date of last follow-up. The Cox proportional 
hazard model was used to study the effects of age on survival 
while adjusting for other important factors. A probability 
value less than 0.05 was considered to be significant. 
Results 
Demographics 
A total of 772 patients with NSCLC were registered during 
the 15-year period. As shown in Table 1, 211 patients (27.3%) 
were 75 years or older, and 72.7% of patients were younger than 
75 years. Men constituted 69.7% in the ≥ 75 age group and 69.2% 
in the <75 age group. Non-adenocarcinomas accounted for 29.4% 
in the ≥75 age group and 22.1% in the <75 age group. Poor PS 
(2–4) accounted for 64.9% in the ≥75 age group and 37.4% in the 
<75 age group (P<0.001). The ≥75 age group had higher incidences 
of comorbid disease (respiratory, cardiovascular, 
neurological, and malignant disease) than those in the <75 age 
group. Incidences of lower serum albumin (<3.5g/dl) and 
elevated serum CRP level (>1.0mg/dl) at the time of NSCLC 
diagnosis in the ≥75 age group were higher than in the <75 age 
group. Best supportive care without chemotherapy or 
radiotherapy was also higher in the ≥75 age group than in the 
<75 age group. Table 2 shows the details regarding the 
first-line medical treatment. There were no apparent trends 
among the three time periods. 
Ratio of the elderly patients who received chemotherapy and 
survival 
Among the ≥75 age group of patients, 12 (26.1%) of 46 
patients received chemotherapy in 1999 to 2003, 37 (40.7%) of 
91 patients received chemotherapy in 2004 to 2008, and 37 (50%) 
of 74 patients received chemotherapy in 2009 to 2013. The ratio 
of the elderly patients who received chemotherapy increased 
significantly (p=0.034). Figure 1 shows the survival curves of 
the ≥75 age group of patients. Median survival of the patients 
during 1999 to 2003, 2004 to 2008, and 2009 to 2013 was 4.7, 
5.7, and 6.1 months, respectively. Figure 2 shows the survival 
curves of the ≥75 age group of patients who were treated with 
chemotherapy. Median survival of the patients during 1999 to 
2003, 2004 to 2008, and 2009 to 2013 was 9.0, 11.9, and 13.5 
months, respectively. There was improvement in survival but it 
was not statistically significant in the log-rank test. 
Comparison of survival between the elderly and the younger 
patients 
Figure 3 shows the comparison of survival between the two 
age groups of patients with chemotherapy. There was no 
statistically significant difference between them (11.9 months 
vs 12.5 months, p=0.883), although the elderly patients in all 
had poorer survival than younger patients (5.4 months vs 8.8 
months, p<0.001). There was no statistically significant 
difference in survival between the two age groups of patients 
with supportive care only (3.0 months vs 2.6 months, p=0.560). 
Prognostic factors 
Table 3 summarizes the relationship between clinical 
variables and survival. In univariate analysis, age more than 
75 years old, male gender, smoking habit, poor PS (PS 2-4), 
non-adenocarcinoma, comorbid respiratory and neurological 
disease, lower level of serum albumin, elevated serum CRP level, 
and no chemotherapy as initial therapy were unfavorable 
prognostic factors. In multivariate analysis, only poor PS, 
lower level of serum albumin, elevated serum CRP level, and no 
chemotherapy as initial therapy were unfavorable prognostic 




There has been increasing interest in the treatment of 
elderly patients with lung cancer [1-5]. However, information 
regarding clinical trends in stage IV NSCLC patients aged ≥75 
years treated with chemotherapy and their survival has not been 
fully available. Aging is associated with a high prevalence of 
comorbid diseases [5, 22-24]. In particular, patients with a 
long smoking history are predisposed to comorbid diseases such 
as chronic obstructive pulmonary disease and cardiovascular 
disease, as well as other smoking-related malignancies [25-27]. 
Therefore, there is considerable scientific uncertainty 
regarding the risks and benefits of chemotherapy in NSCLC 
patients aged ≥75 years. It is debatable whether elderly NSCLC 
patients will do as well as younger patients when chemotherapy 
is administered for their metastatic disease.  
The majority of elderly patients have been denied 
potentially beneficial treatment and participation in clinical 
trials because of the physician perception that they are too 
frail to withstand treatment. On the other hand, some trials 
indicated that ‘fit’ elderly patients benefit from chemotherapy. 
Gridelli et al. reported that there was a survival advantage 
for patients receiving vinorelbine aged 70 years or older in 
the ELVIS trial [6], but non-platinum doublets did not improve 
survival compared to monotherapy in the MILES study [7]. 
Furthermore, some researchers suggested that platinum-based 
doublet chemotherapy benefits elderly patients as well as 
younger patients. Langer et al. suggested that response and 
survival in ‘fit’ elderly patients receiving cisplatin plus 
either etoposide or paclitaxel appear to be similar to those 
in younger patients, although patients 70 years old or older 
have more comorbidities and can expect more leukopenia and 
neuropsychiatric toxicity [8]. Lilenbaum et al. reported that 
the combination of carboplatin and paclitaxel improves response, 
and there was no survival difference in elderly patients 
compared to younger patients [9]. Blanchard et al. reported that 
patients aged 70 years or older derived initial benefit from 
chemotherapy with cicplatin plus vinorelbine and carboplatin 
plus paclitaxel [10]. Belani et al. reported that cisplatin plus 
docetaxel chemotherapy showed similar survival outcomes in 
elderly and younger patient with advanced NSCLC; elderly 
patients tolerated the combination therapy well despite 
experiencing slightly more toxicity than younger patients [11]. 
Ansari et al. reported that overall survival in patients aged 
<70 years and those ≥70 years was similar in doublet 
chemotherapy and that doublet chemotherapy is feasible among 
carefully selected elderly patients with good PS [12]. Recently, 
Quoix et al. reported that carboplatin and weekly paclitaxel 
doublet chemotherapy was associated with survival benefits 
compared with vinorelbine or gemcitabine monotherapy in 
patients aged 70-89 years [13]. Due to the results of this trial, 
the recommendations of the National Comprehensive Cancer 
Network regarding NSCLC chemotherapy in elderly patients were 
modified [14]. 
We previously reviewed the clinical data of the consecutive 
elderly lung cancer patients diagnosed between 1978 and 2007 
at our hospitals [28]. In the study, the ≥80 age group had higher 
prevalence of comorbid disease than the 80< age groups. The 
elderly ≥80 age group was less likely to undergo surgery or 
chemotherapy, and had inferior outcomes compared to the 70–
79 age group and the <70 age group. Survival improvement was 
not observed in the ≥80 age group. Multivariate analysis showed 
that good PS, early clinical stage, and surgery were favorable 
prognostic factors in the ≥80 age group. We could not evaluate 
whether chemotherapy was the prognostic factor due to the small 
number of elderly patients in the previous study. In order to 
clarify the contribution of chemotherapy to survival in the 
elderly, we performed the present study. This time, elderly 
stage IV NSCLC patients were divided into two age groups: the 
≥75 age group and the <75 age group, which is the most used 
division method with regard to age [17-19].  
In the present study, 211 (27.2%) of 772 stage IV NSCLC 
patients were aged ≥75 years. In the ≥75 age group, a higher 
ratio of patients with poor PS and comorbid diseases was 
observed compared to the <75 age group of patients. We revealed 
a trend of increase in patients being treated with chemotherapy 
in the ≥75 age group, and improvement in survival in the ≥75 
age group. In stage IV NSCLC patients who received chemotherapy, 
there was no statistical difference in survival between the ≥75 
age group and the <75 age group, although survival in all of 
the ≥75 age group of patients was shorter than that in the <75 
age group. In univariate analysis, age more than 75 years old, 
male gender, smoking habit, poor PS (PS 2-4), 
non-adenocarcinoma, lower level of serum albumin, elevated 
serum CRP level, and no chemotherapy as initial therapy were 
unfavorable prognostic factors. In multivariate analysis, only 
poor PS, lower level of serum albumin, elevated serum CRP level, 
and no chemotherapy as initial therapy were unfavorable 
prognostic factors. However, Age ≥75 was not an unfavorable 
prognostic factor. Considering this, the improvement in 
survival shown in our study might be dependent on the 
introduction of relatively less toxic drugs such as molecular 
targeting agents, the improvement in supportive care, and the 
construction of widely available health services. 
Our study suffers from limitations imposed by its 
retrospective nature and limited number of patients, but we 
believe that it is important to report clinicopathological 
features and outcomes of stage IV NSCLC in the elderly. The 
increase in number of elderly NSCLC patients will continue, and 
progress in both basic and clinical research for the elderly 
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Figure legends 
Fig 1. Survival curves of the ≥75 age group of patients in three 
time periods. Median survival of the patients during 1999 to 
2003, 2004 to 2008, and 2009- 2013 was 4.7, 5.7, and 6.1 months, 
respectively. 
Fig 2. Survival curves of the ≥75 age group of patients who were 
treated with chemotherapy in three time periods. Median 
survival of the patients during 1999 to 2003, 2004 to 2008, and 
2009- 2013 was 9.0, 11.9, and 13.5 months, respectively. 
Fig 3. Survival curves compared between the ≥75 age group and 
<70 age group of patients who received chemotherapy. There was 
no statistically significant difference between them (11.9 




Table 1. Comparison of clinicopatholofical features between aged ≥75 and <75 years stage IV non-small 
lung cancer patients.   
Variables  patients aged ≥75 patients aged <75 
Number of patients          211 561 
Male patients  147 (69.7%) 388 (69.2%) 
Smoking habit: present   154 (73.0%) 412 (73.4%) 
Performance status: 2-4  137 (64.9%) 210 (37.4%) ** 
Non-adenocarcinoma 62 (29.4%) 124 (22.1%) * 
  Comorbidity 
Respiratory disease 63 (29.9%) 121 (21.6%) * 
Cardiovascular disease 123 (58.3%) 176 (31.4%) ** 
Neurological disease 30 (14.2%) 33 (5.9%) ** 
Diabetes mellitus 44 (20.9%) 91 (16.2%) 
Malignant disease# 34 (16.1%) 51 (9.1%) ** 
Serum albumin (<3.5g/dl) 95 (45.0%)           190 (33.9%)       ** 
Serum CRP (>1.0ml/dl) 314 (58.7%)  91 (38.4%) ** 
*: p<0.05, **: p<0.01  #Malignant disease included past and concurrent diseases. 
Table 2. Detail of 1st line treatment given in each time period. 
1999-2003 2004-2008 2009-2013 
Treatment <75 ≥75 <75 ≥75 <75 ≥75 
Platinum doublet 74 (46.5%) 2 (4.3%) 131 (63.3%) 13 (14.3%) 133 (68.2%) 15 (20.3%) 
 with Bevacizumab 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 11 (5.6%) 1 (1.4%) 
Single agent 4 (2.5%) 3 (6.5%) 10 (4.8%) 21 (23.1%) 6 (3.1%) 11 (14.9%) 
EGFR-TKI 15 (9.4%) 6 (13.0%) 12 (5.8%) 2 (2.2%) 29 (14.9%) 11 (14.9%) 
Other 2 (1.3%) 1 (2.2%) 1 (0.5%) 1 (1.1%) 0 (0.0%) 0 (0.0%) 
Supportive care only 64 (40.3%) 34 (73.9%) 53 (25.6%) 54 (59.3%) 27 (13.8%) 37 (50.0%) 
EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor 
Table 3. Univariate and multivariate analyses of prognostic factors in 211 aged ≥75 patients 
with stage IV non-small cell lung cancer 
Univariate analysis Multivariate analysis 
Factors (log-rank test) (Cox`s proportional hazards model) 
P-value      hazard ratio 95%CI P-value 
Age ≥75 years <0.001 0.83 0.68-1.01 0.060 
Male <0.001 1.19 0.92-1.53 0.182 
Smoking habit: present <0.001 1.08 0.82-1.41 0.583 
Performance status: 2-4  <0.001 1.87 1.54-2.26 <0.001 
Non-adenocarcinoma <0.001 1.14 0.94-1.39 0.187 
Comorbid respiratory disease 0.038 1.04 0.86-1.26 0.711 
Comorbid neurological disease 0.040 0.95 0.69-1.32 0.776 
Serum albumin<3.5g/dl <0.001 1.29 1.07-1.55 0.007 
Serum CRP>1.0mg/dl <0.001 1.65 1.37-2.00 <0.001 
Supportive care only <0.001 2.92 2.38-3.59 <0.001 
95%CI: 95% confidence interval 
